Hims & Hers Health, a telehealth company, is planning to offer a generic version of Novo Nordisk's diabetes drug, liraglutide ...

Hims & Hers Health (HIMS) stock gains after its Q3 2024 results as company plans to launch a generic version of Novo ...

The millennial-skewed telehealth platform Hims & Hers (HIMS) announced Monday that it will start offering customers a generic version of liraglutide, an older GLP-1 weight loss drug, next year. The ...

A study published Wednesday suggests a surprising side effect of GLP-1 drugs such as Ozempic: they can be effective at ...

and liraglutide with a 22% lower risk. The risk of hospitalization when using GLP-1-agonists was lower than when using ...

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Semaglutide and liraglutide are associated with reduced AUD and SUD-related ... according to the 2023 National Survey on Drug ...

"We plan to bring liraglutide, the first generic GLP-1 in the market, to the platform in 2025," Dudum said, referring to the injectable, marketed as Victoza and Saxenda for diabetes and obesity ...

Hims & Hers currently offers compounded GLP-1 weight-loss injections at $199 per month and weight management oral medication ...

Both drugs come as an injection. Ozempic and Victoza are not available as generic drugs. This article explains the main ways that Ozempic and Victoza are alike and different. For more information ...